Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
Melanie Widenmeyer, Heinrich Griesemann, Stefan Stevanović, Susan Feyerabend, Reinhild Klein, Sebastian Attig, Jörg Hennenlotter, Dorothee Wernet, Dmitri V. Kuprash, Alexei Y. Sazykin, Steve Pascolo,Volume:
131
Year:
2012
Language:
english
Pages:
10
DOI:
10.1002/ijc.26365
File:
PDF, 1.26 MB
english, 2012